[1] FISHER B,BRYANT J,WOLMARK N,et al.Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J].J Clin Oncol,1998,16(8):2672-2685.
[2] MAURIAC L,MacGROGAN G,AVRIL A,et al.Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm:a unicentre randomized trial with a 124-month median follow-up[J].Ann Oncol,1999,10(1):47-52.
[3] BROËT P,SCHOLL S M,de la ROCHEFORDIERE A,et al.Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy:an updated analysis of a randomized trial[J].Breast Cancer Res Treat,1999,58(2):151-156.
[4] BONADONNA G,VALAGUSSA P,BRAMBILLA C,et al.Primary chemotherapy in operable breast cancer:eight-year experience at the Milan Cancer Institute[J].J Clin Oncol,1998,16(1):93-100.
[5] van der HAGE J A,van de VELDE C J H,JULIEN J P,et al.Preoperative chemotherapy in primary operable breast cancer:results from the European Organization for Research and Treatment of Cancer trial 10902[J].J Clin Oncol,2001,19(22):4224-4237.
[6] BONADONNA G,VERONESI U,BRAMBILLA C,et al.Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more[J].J Nat Cancer Inst,1990,82(19):1539-1545.
[7] GIANNI L,BASELGA J,EIERMANN W,et al.Phase Ⅲ trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide,methotrexate,and fluorouracil,as adjuvant or primary systemic therapy:European Cooperative Trial in Operable Breast Cancer[J].J Clin Oncol,2009,27(15):2474-2481.
[8] 李卉,廖传贵,何小梅.晚期乳腺癌新辅助化疗的临床报告[J].中国普外基础与临床杂志,2004,11(1):20-21.
[9] BHALLA K,HARRIS W B.Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer[C]//Seminars in oncology.Elsevier,1998,25(2):19-24.
[10] RASTOGI P,ANDERSON S J,BEAR H D,et al.Preoperative chemotherapy:updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J].J Clin Oncol,2008,26(5):778-785.
[11] MALAMOS N,KOSMAS C,ANTONOPOULOS M J,et al.Prospective randomized study of neoadjuvant chemotherapy (NACT) with paclitaxel/epirubicin (PE) versus fluorouracil/epirubicin/cyclophosphamide (FEC) in operable stage Ⅱ-ⅢA breast cancer (BC)[C]//Annals of Oncology.Spuiboulevard 50,PO BOX 17,3300 AA DORDRECHT,NETHERLANDS:KLUWER ACADEMIC PUBL,1998,9:22-23.
[12] BEAR H D,ANDERSON S,BROWN A,et al.The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide:preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J].J Clin Oncol,2003,21(22):4165-4174.
[13] LUPORSI E,VANLEMMENS L,COUDERT B,et al.Cycles of FEC 100 vs 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (pts):preliminary results of a randomized phase Ⅱ trial of GIREC S01[C]//Proc Am Soc Clin Oncol,2000,19:92a.
[14] STEGER G G,GALID A,GNANT M,et al.Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer:results of ABCSG-14[J].J Clin Oncol,2007,25(15):2012-2018.
[15] VINCENT-SALOMON A,ROUSSEAU A,JOUVE M,et al.Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy[J].Eur J Cancer,2004,40(10):1502-1508.
[16] BOTTINI A,BERRUTI A,BERSIGA A,et al.Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer[J].Br J Cancer,2001,85(8):1106-1112.
[17] PETIT T,WILT M,VELTEN M,et al.Comparative value of tumour grade,hormonal receptors,Ki-67,HER-2 and topoisomerase Ⅱ alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy[J].Eur J Cancer,2004,40(2):205-211.
[18] FANEYTE I F,SCHRAMA J G,PETERSE J L,et al.Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome[J].Br J Cancer,2003,88(3):406-412.
[19] 谢菲,周波,曹迎明,等.不同生物学标志物对乳腺癌新辅助化疗疗效的预测价值[J].中国癌症杂志,2010,20(6):452-456.
[20] ESTVEZ L G,CUEVAS J M,ANTÓN A,et al.Weekly docetaxel as neoadjuvant chemotherapy for stage Ⅱ and Ⅲ breast cancer efficacy and correlation with biological markers in a phase Ⅱ.Multicenter Study[J].Clin Cancer Res,2003,9(2):686-692.
[21] 胡波飞,贾明,魏素菊.Ki-67 与传统生物学标志物预测乳腺癌化疗药物敏感性的研究进展[J].现代肿瘤医学,2012,20(4):853-856.
[22] COLLEONI M,VIALE G,ZAHRIEH D,et al.Expression of ER,PgR,HER1,HER2,and response:a study of preoperative chemotherapy[J].Annals of oncology,2008,19(3):465-472.
[23] GUARNERI V,BROGLIO K,KAU S W,et al.Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors[J].J Clin Oncol,2006,24(7):1037-1044.
[24] JONES R L,SALTER J,A'HERN R,et al.Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer[J].Breast Cancer Res Treat,2010,119(2):315-323.
[25] OGSTON K N,MILLER I D,SCHOFIELD A C,et al.Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?[J].Breast Cancer Res Treat,2004,86(2):181-189.
[26] 韩芸蔚,温绍艳,刘伟,等.乳腺癌新辅助化疗的临床评价方法解析[J].中国肿瘤临床,2011,38(7):415-418.
[27] 吴艳艳,彭玉兰.乳腺癌新辅助化疗的影像学评价[J].临床超声医学杂志,2010,12(4):258-261.
[28] TOZAKI M,UNO S,KOBAYASHI T,et al.Histologic breast cancer extent after neoadjuvant chemotherapy:comparison with multidetector-row CT and dynamic MRI[J].Radiat Med,2003,22(4):246-253.
[29] IZZO L,STASOLLA A,BASSO L,et al.Characterization of tumoral lesions of the breast:preliminary experience with multislice spiral CT[J].J Exp Clin Cancer Res,2005,24(2):209-214.
[30] NASON K S,ANDERSON B O,BYRD D R,et al.Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma[J].Cancer,2000,89(11):2187-2194.
[31] BRESLIN T M,COHEN L,SAHIN A,et al.Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer[J].J Clin Oncol,2000,18(20):3480-3486.
[32] TACCA O,PENAULT-LIORCA F,ABRIAL C,et al.Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy[J].Oncologist,2007,12(6):636-643.
[33] 蒋文英,桑剑锋,苏磊,等.乳腺癌新辅助化疗疗效及其判断方法[J].现代医学,2011,39(2):237-240.
[34] 单海琳,李俊生,邵清.乳腺癌组织中 ADAM8 mRNA 的表达及意义[J].南大学学报:医学版,2011,30(6):822-826. |
